OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 2,191 argenex SE $ARGX

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of argenex SE (NASDAQ:ARGX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,191 shares of the company’s stock, valued at approximately $1,208,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ARGX. Goldman Sachs Group Inc. grew its holdings in shares of argenex by 14.8% during the first quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock valued at $99,886,000 after buying an additional 21,805 shares during the last quarter. Amundi lifted its position in argenex by 8.1% in the 1st quarter. Amundi now owns 6,351 shares of the company’s stock valued at $3,747,000 after acquiring an additional 478 shares in the last quarter. Voya Investment Management LLC lifted its position in argenex by 5.2% in the 1st quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock valued at $8,822,000 after acquiring an additional 735 shares in the last quarter. Royal Bank of Canada boosted its stake in argenex by 0.9% during the 1st quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock valued at $22,673,000 after purchasing an additional 353 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in argenex by 40.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,611 shares of the company’s stock worth $2,542,000 after purchasing an additional 1,328 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $889.49 on Friday. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62. The company has a market capitalization of $54.77 billion, a PE ratio of 38.19, a price-to-earnings-growth ratio of 0.90 and a beta of 0.37. The business has a fifty day moving average price of $861.72 and a two-hundred day moving average price of $714.26.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. Sell-side analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARGX has been the topic of a number of recent research reports. Evercore ISI raised their target price on argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Bank of America increased their price target on argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Stifel Nicolaus raised their price objective on argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a research note on Thursday. Jefferies Financial Group set a $818.00 target price on shares of argenex and gave the stock a “buy” rating in a research note on Tuesday, August 26th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average target price of $968.83.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.